SCHEMBL10183281

SCHEMBL10183281

CC(C)(C)c1cc2c(cn1)ncn2C1CN(CCO)C1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.35
DRD2 P14416 1/20 0.33
SLC6A4 P31645 1/20 0.33
CNR2 P34972 1/20 0.32
GLRA3 O75311 1/20 0.32
GLRB P48167 1/20 0.32
IDO1 P14902 4/20 0.31
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30
GAA P10253 1/20 0.30
THRB P10828 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
TYK2 P29597 1/20 0.30
JAK3 P52333 1/20 0.30
PRMT5 O14744 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10183159 0.86 JAK1 (0.35) DRD2SLC6A4GLRA3GLRBIDO1
SCHEMBL10183230 0.84 GLRA3 (0.35) DRD2SLC6A4GLRA3GLRBIDO1
SCHEMBL10235449 0.81 DRD2 (0.36) DRD2SLC6A4GLRA3GLRBIDO1
SCHEMBL10183640 0.81 DRD2 (0.43) DRD2SLC6A4CNR2ALDH1A1LMNA
SCHEMBL10183158 0.81 DRD2 (0.43) DRD2SLC6A4CNR2ALDH1A1LMNA
SCHEMBL10183626 0.80 EGFR (0.40) DRD2SLC6A4IDO1ALDH1A1LMNA
SCHEMBL10183263 0.79 GLRA3 (0.41) CNR2GLRA3GLRBIDO1ALDH1A1
SCHEMBL10183257 0.79 IDO1 (0.37) IDO1ALDH1A1GAA
SCHEMBL10183244 0.79 IDO1 (0.35) GLRA3GLRBIDO1ALDH1A1HPGD
SCHEMBL10183124 0.78 EGFR (0.42) ALDH1A1LMNAGAAHPGDJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF SYK 1442/4885DRD2 4814/4885SLC6A4 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.